Matthew R. Kwietniak
2023
Compensation breakdown
| Non-Equity Incentive Plan | $146,700 |
|---|---|
| Salary | $360,154 |
| Stock Awards | $730,298 |
| Other | $46,732 |
| Total | $1,283,884 |
Kwietniak received $730.3K in stock awards, accounting for 57% of the total pay in 2023.
Kwietniak also received $146.7K in non-equity incentive plan, $360.2K in salary and $46.7K in other compensation.
Rankings
In 2023, Matthew R. Kwietniak's compensation ranked 858th out of 2,248 executives tracked by ExecPay. In other words, Kwietniak earned more than 61.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 858 out of 2,248 | 62nd |
Division Manufacturing | 504 out of 1,223 | 59th |
Major group Chemicals And Allied Products | 342 out of 687 | 50th |
Industry group Drugs | 332 out of 658 | 50th |
Industry Pharmaceutical Preparations | 226 out of 472 | 52nd |
Pay ratio
| Matthew R. Kwietniak's Pay | $1,283,884 |
|---|---|
| Median Employee's Pay | $104,595 |
| Pay Ratio | 12to 1 |
In 2023, the annual total compensation of Matthew R. Kwietniak was $1,283,884.
The annual total compensation of the median employee at Peregrine Pharmaceuticals was $104,595.
The ratio of Matthew R. Kwietniak's pay to the pay of median employee was therefore 12 to one.
Kwietniak's colleagues
We found four more compensation records of executives who worked with Matthew R. Kwietniak at Peregrine Pharmaceuticals in 2023.